N
ATOS icon

Nuveen’s Atossa Therapeutics ATOS Stock Holding History

Nuveen’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,382
Closed -$115K – 3285
2025
Q1 		$115K Hold
11,382
– – ﹤0.01% 3203
2024
Q4 		$161K Hold
11,382
– – ﹤0.01% 3239
2024
Q3 		$260K Hold
11,382
– – ﹤0.01% 3178
2024
Q2 		$203K Buy
+11,382
New +$252K ﹤0.01% 3213
2022
Q2 		– Sell
-135,157
Closed -$3.18M – 3251
2022
Q1 		$3.18M Buy
135,157
+32,457
+32% +$659K ﹤0.01% 2289
2021
Q4 		$2.87M Sell
102,700
-3,564
-3% -$130K ﹤0.01% 2390
2021
Q3 		$5.71M Buy
106,264
+33,122
+45% +$1.93M ﹤0.01% 2129
2021
Q2 		$6.93M Buy
+73,142
New +$3.87M ﹤0.01% 2078

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $431B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $93.1B AUM 61.18% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return